AER 1522233 is a spontaneous case, received on 15/Jan/2015 from a physician via company representative and 
concerns a patient of unspecified demographics while being treated with rituximab (Rituxan).
The patient's concomitant medications included prednisone and ciclosporin. Medical history, concurrent conditions 
or past medications were not reported.
On an unspecified date, the patient started with rituximab (dose, route, form and frequency was unknown) for lupus.
Later, the patient developed biopsy proven (life threatening) PML (progressive multifocal leukoencephalopathy).
At the time of this report, outcome of progressive multifocal leukoencephalopathy was not reported and therapy 
status of rituximab was unknown.
The physician did not asses the causal relationship of progressive multifocal leukoencephalopathy with rituximab.
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 378 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
No further information was provided.